NICE accelerates breakthrough framework for complex liver diseases
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
NICE drives innovation, reshaping MASH evaluations with transformative guidance.
Global market access shifts: HTA speed, UK pricing, digital disruption.
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.